Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
09:37am, Monday, 04'th Dec 2023
Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
07:43am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke
Roche Acquiring Obesity Drug Maker Carmot for $3.1 Billion
06:17am, Monday, 04'th Dec 2023
Roche Holding AG will pay as much as $3.1 billion for Carmot Therapeutics Inc., in a deal that includes three experimental medicines in obesity and diabetes. Eric Pfanner reports on Bloomberg Televisi
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic
05:40am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No
Roche to acquire Carmot Therapeutics for $2.7 bln
01:13am, Monday, 04'th Dec 2023
Pharmaceutical giant Roche said on Monday it has entered into a definitive agreement to acquire Carmot Therapeutics , a US company based in Berkeley.
David Roche says U.S. inflation won't reach 2%
12:04am, Monday, 04'th Dec 2023
David Roche of Independent Strategy says it's clear that the U.S. Federal Reserve is done raising interest rates, "which means the next move is down."
Is Roche Stock Undervalued At $33?
09:00am, Wednesday, 29'th Nov 2023
After a 14% fall this year, Roche stock (OTCMKTS: RHHBY) looks like it can see higher levels.
Roche investing $240 million in Colombia over five years - country general manager
11:59am, Thursday, 16'th Nov 2023
Swiss drugs and diagnostics maker Roche is investing $240 million in Colombia over five years as part of its plan to consolidate its presence in the country, a high-ranking executive said on Thursday.
Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion
02:17pm, Tuesday, 14'th Nov 2023
Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.
Roivant cash-flush after $7.15B Telavant sale to Roche as it reports mixed 3Q
08:13am, Monday, 13'th Nov 2023
Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts' expectations, sending its shares higher in Monday premarket trading. The company also said it has sufficie
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
06:50am, Friday, 10'th Nov 2023
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
The U.S. can avoid a recession, David Roche says
01:04am, Monday, 06'th Nov 2023
David Roche, president and global strategist at Independent Strategy, says "American households have done nothing but get richer."
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
08:45am, Saturday, 28'th Oct 2023
Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
03:28pm, Monday, 23'rd Oct 2023
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a fi
Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion
03:25pm, Monday, 23'rd Oct 2023
London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.
